BRISTOL-MYERS SQUIBB COMPANY Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount of $341.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationOtherReconcilingItems · last filed 2026-02-11
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, other reconciling items, amount for fiscal 2024 was $341.00M, a 106.67% increase from fiscal 2023.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, other reconciling items, amount for fiscal 2023 was $165.00M, a 18.71% increase from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, other reconciling items, amount for fiscal 2022 was $139.00M, a 0.72% increase from fiscal 2021.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, other reconciling items, amount for fiscal 2021 was $138.00M, a 9.52% increase from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount 12 month | Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount 12 month as first filed |
|---|---|---|
| 2024-12-31 | $341.00M 10-K · filed 2026-02-11 | |
| 2023-12-31 | $165.00M 10-K · filed 2026-02-11 | |
| 2022-12-31 | $139.00M 10-K · filed 2025-02-12 | $197.00M 10-K · filed 2023-02-14 |
| 2021-12-31 | $138.00M 10-K · filed 2024-02-13 | $60.00M 10-K · filed 2022-02-09 |
| 2020-12-31 | $126.00M 10-K · filed 2023-02-14 | $42.00M 10-K · filed 2021-02-10 |
| 2019-12-31 | -$96.00M 10-K · filed 2022-02-09 | -$121.00M 10-K · filed 2020-02-24 |
| 2018-12-31 | $74.00M 10-K · filed 2021-02-10 | $53.00M 10-K · filed 2019-02-25 |
| 2017-12-31 | -$37.00M 10-K · filed 2020-02-24 | -$93.00M 10-K · filed 2018-02-13 |
| 2016-12-31 | -$90.00M 10-K · filed 2019-02-25 | |
| 2015-12-31 | $32.00M 10-K · filed 2018-02-13 | -$40.00M 10-K · filed 2016-02-12 |
| 2014-12-31 | -$46.00M 10-K · filed 2017-02-21 | -$74.00M 10-K · filed 2015-02-13 |
| 2013-12-31 | -$73.00M 10-K · filed 2016-02-12 | -$122.00M 10-K · filed 2014-02-14 |
| 2012-12-31 | -$45.00M 10-K · filed 2015-02-13 | -$76.00M 10-K · filed 2013-02-15 |
| 2011-12-31 | -$12.00M 10-K · filed 2014-02-14 | |
| 2010-12-31 | $69.00M 10-K · filed 2013-02-15 | |
| 2009-12-31 | -$50.00M 10-K · filed 2012-02-17 | |
| 2008-12-31 | $66.00M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |